{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T12:12:47Z","timestamp":1792843967971,"version":"4.5.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T00:00:00Z","timestamp":1489622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,3,16]],"date-time":"2017-03-16T00:00:00Z","timestamp":1489622400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Lymphatic filariasis (LF) and onchocerciasis are priority neglected tropical diseases targeted for elimination. The only safe drug treatment with substantial curative activity against the filarial nematodes responsible for LF (\n                    <jats:italic>Brugia malayi, Wuchereria bancrofti<\/jats:italic>\n                    ) or onchocerciasis (\n                    <jats:italic>Onchocerca volvulus<\/jats:italic>\n                    ) is doxycycline. The target of doxycycline is the essential endosymbiont,\n                    <jats:italic>Wolbachia.<\/jats:italic>\n                    Four to six weeks doxycycline therapy achieves &gt;90% depletion of\n                    <jats:italic>Wolbachia<\/jats:italic>\n                    in worm tissues leading to blockade of embryogenesis, adult sterility and premature death 18\u201324 months post-treatment. Long treatment length and contraindications in children and pregnancy are obstacles to implementing doxycycline as a public health strategy. Here we determine, via preclinical infection models of\n                    <jats:italic>Brugia malayi<\/jats:italic>\n                    or\n                    <jats:italic>Onchocerca ochengi<\/jats:italic>\n                    that elevated exposures of orally-administered rifampicin can lead to\n                    <jats:italic>Wolbachia<\/jats:italic>\n                    depletions from filariae more rapidly than those achieved by doxycycline. Dose escalation of rifampicin achieves &gt;90%\n                    <jats:italic>Wolbachia<\/jats:italic>\n                    depletion in time periods of 7 days in\n                    <jats:italic>B. malayi<\/jats:italic>\n                    and 14 days in\n                    <jats:italic>O. ochengi<\/jats:italic>\n                    . Using pharmacokinetic-pharmacodynamic modelling and mouse-human bridging analysis, we conclude that clinically relevant dose elevations of rifampicin, which have recently been determined as safe in humans, could be administered as short courses to filariasis target populations with potential to reduce anti-\n                    <jats:italic>Wolbachia<\/jats:italic>\n                    curative therapy times to between one and two weeks.\n                  <\/jats:p>","DOI":"10.1038\/s41598-017-00322-5","type":"journal-article","created":{"date-parts":[[2017,3,10]],"date-time":"2017-03-10T06:53:59Z","timestamp":1489128839000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5288-4501","authenticated-orcid":false,"given":"Ghaith","family":"Aljayyoussi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley E.","family":"Tyrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7919-2866","authenticated-orcid":false,"given":"Louise","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Sjoberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Pionnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Waterhouse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Gamble","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haelly","family":"Metuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren A. N.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Steven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana F.","family":"Guimaraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel H.","family":"Clare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Cassidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly L.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Myhill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hayward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Wanji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Turner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,16]]},"reference":[{"key":"322_CR1","unstructured":"WHO. Meeting of the International Task Force for Disease Eradication, January 2014. Releve epidemiologique hebdomadaire\/Section d\u2019hygiene du Secretariat de la Societe des Nations=Weekly epidemiological record\/Health Section of the Secretariat of the League of Nations 89, 153\u2013160 (2014)."},{"key":"322_CR2","doi-asserted-by":"publisher","first-page":"20120144","DOI":"10.1098\/rstb.2012.0144","volume":"368","author":"MJ Bockarie","year":"2013","unstructured":"Bockarie, M. J., Kelly-Hope, L. A., Rebollo, M. & Molyneux, D. H. Preventive chemotherapy as a strategy for elimination of neglected tropical parasitic diseases: endgame challenges. Philosophical Transactions of the Royal Society of London B: Biological Sciences 368, 20120144 (2013).","journal-title":"Philosophical Transactions of the Royal Society of London B: Biological Sciences"},{"key":"322_CR3","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/S0140-6736(10)60586-7","volume":"376","author":"MJ Taylor","year":"2010","unstructured":"Taylor, M. J., Hoerauf, A. & Bockarie, M. Lymphatic filariasis and onchocerciasis. Lancet 376, 1175\u20131185, https:\/\/doi.org\/10.1016\/S0140-6736(10)60586-7 (2010).","journal-title":"Lancet"},{"key":"322_CR4","unstructured":"WHO. Lymphatic Filariasis Factsheet, <http:\/\/www.who.int\/mediacentre\/factsheets\/fs102\/en\/.> (2016)."},{"issue":"Suppl 2","key":"322_CR5","doi-asserted-by":"publisher","first-page":"S15","DOI":"10.1179\/000349802125002374","volume":"96","author":"DH Molyneux","year":"2002","unstructured":"Molyneux, D. H. & Zagaria, N. Lymphatic filariasis elimination: progress in global programme development. Annals of tropical medicine and parasitology 96(Suppl 2), S15\u201340 (2002).","journal-title":"Annals of tropical medicine and parasitology"},{"key":"322_CR6","unstructured":"[APOC], A. P. f. O. C. In Joint Action Forum (JAF) of APOC (Paris, France, 2005)."},{"key":"322_CR7","unstructured":"WHO. Onchocerciasis Factsheet No 374 (2016)."},{"key":"322_CR8","unstructured":"WHO. Onchocerciasis and its control: Report of a WHO Expert Committee on Onchocerciasis Control (1995)."},{"key":"322_CR9","unstructured":"WHO. African Programme for Onchocerciasis Control - report of the sixth meeting of National Task Forces, October 2009. Releve epidemiologique hebdomadaire\/Section d\u2019hygiene du Secretariat de la Societe des Nations\u2009=\u2009Weekly epidemiological record\/Health Section of the Secretariat of the League of Nations 85, 23\u201328 (2010)."},{"key":"322_CR10","unstructured":"WHO. Global Plan to Combat Neglected Tropical Diseases 2008\u20132017, <http:\/\/apps.who.int\/iris\/bitstream\/10665\/69708\/1\/WHO_CDS_NTD_2007.3_eng.pdf> (2007)."},{"key":"322_CR11","unstructured":"WHO. Accelerating Work to Overcome the Global Impact of Neglected Tropical Diseases: A Roadmap for Implementation, <http:\/\/www.who.int\/neglected_diseases\/NTD_RoadMap_2012_Fullversion.pdf> (2012)."},{"key":"322_CR12","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.pt.2003.09.004","volume":"19","author":"DH Molyneux","year":"2003","unstructured":"Molyneux, D. H., Bradley, M., Hoerauf, A., Kyelem, D. & Taylor, M. J. Mass drug treatment for lymphatic filariasis and onchocerciasis. Trends in parasitology 19, 516\u2013522 (2003).","journal-title":"Trends in parasitology"},{"key":"322_CR13","first-page":"491","volume":"75","author":"E Ottesen","year":"1997","unstructured":"Ottesen, E., Duke, B., Karam, M. & Behbehani, K. Strategies and tools for the control\/elimination of lymphatic filariasis. Bulletin of the world Health Organization 75, 491 (1997).","journal-title":"Bulletin of the world Health Organization"},{"issue":"Suppl 1","key":"322_CR14","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1080\/00034983.1998.11813373","volume":"92","author":"OO Kale","year":"1998","unstructured":"Kale, O. O. Onchocerciasis: the burden of disease. Annals of tropical medicine and parasitology 92(Suppl 1), S101\u2013115 (1998).","journal-title":"Annals of tropical medicine and parasitology"},{"key":"322_CR15","doi-asserted-by":"publisher","first-page":"e3328","DOI":"10.1371\/journal.pntd.0003328","volume":"8","author":"K Ichimori","year":"2014","unstructured":"Ichimori, K. et al. Global programme to eliminate lymphatic filariasis: the processes underlying programme success. PLoS Negl Trop Dis 8, e3328 (2014).","journal-title":"PLoS Negl Trop Dis"},{"key":"322_CR16","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/QCO.0b013e32833fdee5","volume":"23","author":"MJ Bockarie","year":"2010","unstructured":"Bockarie, M. J. & Deb, R. M. Elimination of lymphatic filariasis: do we have the drugs to complete the job? Current opinion in infectious diseases 23, 617\u2013620, https:\/\/doi.org\/10.1097\/QCO.0b013e32833fdee5 (2010).","journal-title":"Current opinion in infectious diseases"},{"key":"322_CR17","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1586\/14787210.2013.811841","volume":"11","author":"MP Rebollo","year":"2013","unstructured":"Rebollo, M. P. & Bockarie, M. J. Toward the elimination of lymphatic filariasis by 2020: treatment update and impact assessment for the endgame. Expert review of anti-infective therapy 11, 723\u2013731 (2013).","journal-title":"Expert review of anti-infective therapy"},{"key":"322_CR18","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1517\/14656566.6.2.179","volume":"6","author":"JO Gyapong","year":"2005","unstructured":"Gyapong, J. O., Kumaraswami, V., Biswas, G. & Ottesen, E. A. Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert opinion on pharmacotherapy 6, 179\u2013200 (2005).","journal-title":"Expert opinion on pharmacotherapy"},{"key":"322_CR19","doi-asserted-by":"publisher","first-page":"e2032","DOI":"10.1371\/journal.pntd.0002032","volume":"7","author":"LE Coffeng","year":"2013","unstructured":"Coffeng, L. E. et al. African Programme For Onchocerciasis Control 1995\u20132015: model-estimated health impact and cost. PLoS Negl Trop Dis 7, e2032, https:\/\/doi.org\/10.1371\/journal.pntd.0002032 (2013).","journal-title":"PLoS Negl Trop Dis"},{"key":"322_CR20","doi-asserted-by":"publisher","first-page":"e371","DOI":"10.1371\/journal.pmed.0030371","volume":"3","author":"M-G Bas\u00e1\u00f1ez","year":"2006","unstructured":"Bas\u00e1\u00f1ez, M.-G. et al. River blindness: a success story under threat? PLoS Med 3, e371 (2006).","journal-title":"PLoS Med"},{"key":"322_CR21","doi-asserted-by":"publisher","first-page":"e2080","DOI":"10.1371\/journal.pntd.0002080","volume":"7","author":"YK Sodahlon","year":"2013","unstructured":"Sodahlon, Y. K. et al. A success story: Togo is moving toward becoming the first sub-Saharan African nation to eliminate lymphatic filariasis through mass drug administration and countrywide morbidity alleviation. PLoS Negl Trop Dis 7, e2080 (2013).","journal-title":"PLoS Negl Trop Dis"},{"key":"322_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2049-9957-2-30","volume":"2","author":"S De-jian","year":"2013","unstructured":"De-jian, S., Xu-li, D. & Ji-hui, D. The history of the elimination of lymphatic filariasis in China. Infectious diseases of poverty 2, 1 (2013).","journal-title":"Infectious diseases of poverty"},{"key":"322_CR23","unstructured":"WHO. Expert Mission to Sri Lanka for verification of elimination of lymphatic filariasis. (World Health Organisation, New Delhi, India, 2012)."},{"key":"322_CR24","doi-asserted-by":"publisher","first-page":"323","DOI":"10.3347\/kjp.2009.47.4.323","volume":"47","author":"HI Cheun","year":"2009","unstructured":"Cheun, H. I. et al. Successful control of lymphatic filariasis in the Republic of Korea. The Korean journal of parasitology 47, 323\u2013335, https:\/\/doi.org\/10.3347\/kjp.2009.47.4.323 (2009).","journal-title":"The Korean journal of parasitology"},{"key":"322_CR25","first-page":"577","volume":"90","author":"WHO","year":"2015","unstructured":"WHO. Progress toward eliminating onchocerciasis in the WHO Region of the Americas: verification of elimination of transmission in Mexico. Releve epidemiologique hebdomadaire\/Section d\u2019hygiene du Secretariat de la Societe des Nations\u2009=\u2009Weekly epidemiological record\/Health Section of the Secretariat of the League of Nations 90, 577\u2013581 (2015).","journal-title":"Releve epidemiologique hebdomadaire\/Section d\u2019hygiene du Secretariat de la Societe des Nations\u2009=\u2009Weekly epidemiological record\/Health Section of the Secretariat of the League of Nations"},{"key":"322_CR26","first-page":"401","volume":"89","author":"WHO","year":"2014","unstructured":"WHO. Elimination of onchocerciasis in the WHO Region of the Americas: Ecuador\u2019s progress towards verification of elimination. Releve epidemiologique hebdomadaire\/Section d\u2019hygiene du Secretariat de la Societe des Nations\u2009=\u2009Weekly epidemiological record\/Health Section of the Secretariat of the League of Nations 89, 401\u2013405 (2014).","journal-title":"Releve epidemiologique hebdomadaire\/Section d\u2019hygiene du Secretariat de la Societe des Nations\u2009=\u2009Weekly epidemiological record\/Health Section of the Secretariat of the League of Nations"},{"key":"322_CR27","first-page":"381","volume":"88","author":"WHO","year":"2013","unstructured":"WHO. Progress towards eliminating onchocerciasis in the WHO Region of the Americas: verification by WHO of elimination of transmission in Colombia. Releve epidemiologique hebdomadaire\/Section d\u2019hygiene du Secretariat de la Societe des Nations\u2009=\u2009Weekly epidemiological record\/Health Section of the Secretariat of the League of Nations 88, 381\u2013385 (2013).","journal-title":"Releve epidemiologique hebdomadaire\/Section d\u2019hygiene du Secretariat de la Societe des Nations\u2009=\u2009Weekly epidemiological record\/Health Section of the Secretariat of the League of Nations"},{"key":"322_CR28","doi-asserted-by":"publisher","first-page":"e497","DOI":"10.1371\/journal.pntd.0000497","volume":"3","author":"L Diawara","year":"2009","unstructured":"Diawara, L. et al. Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal. PLoS Negl Trop Dis 3, e497, https:\/\/doi.org\/10.1371\/journal.pntd.0000497 (2009).","journal-title":"PLoS Negl Trop Dis"},{"key":"322_CR29","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1371\/journal.pntd.0000072","volume":"1","author":"C Bourguinat","year":"2007","unstructured":"Bourguinat, C. et al. Genetic selection of low fertile Onchocerca volvulus by ivermectin treatment. PLoS Negl Trop Dis 1, e72, https:\/\/doi.org\/10.1371\/journal.pntd.0000072 (2007).","journal-title":"PLoS Negl Trop Dis"},{"key":"322_CR30","doi-asserted-by":"publisher","first-page":"e998","DOI":"10.1371\/journal.pntd.0000998","volume":"5","author":"MY Osei-Atweneboana","year":"2011","unstructured":"Osei-Atweneboana, M. Y. et al. Phenotypic evidence of emerging ivermectin resistance in Onchocerca volvulus. PLoS Negl Trop Dis 5, e998 (2011).","journal-title":"PLoS Negl Trop Dis"},{"key":"322_CR31","first-page":"20","volume":"2","author":"MY Osei-Atweneboana","year":"2012","unstructured":"Osei-Atweneboana, M. Y., Boakye, D. A., Awadzi, K., Gyapong, J. O. & Prichard, R. K. Genotypic analysis of \u03b2-tubulin in Onchocerca volvulus from communities and individuals showing poor parasitological response to ivermectin treatment. International Journal for Parasitology: Drugs and Drug Resistance 2, 20\u201328 (2012).","journal-title":"International Journal for Parasitology: Drugs and Drug Resistance"},{"key":"322_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-3305-2-7","volume":"2","author":"MJ Taylor","year":"2009","unstructured":"Taylor, M. J. et al. Onchocerciasis Control: Vision for the Future from a Ghanian perspective. Parasites & vectors 2, 1 (2009).","journal-title":"Parasites & vectors"},{"key":"322_CR33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0140-6736(96)11094-1","volume":"350","author":"J Gardon","year":"1997","unstructured":"Gardon, J., Gardon-Wendel, N., Kamgno, J., Chippaux, J.-P. & Boussinesq, M. Serious reactions after mass treatment of onchocerciasis with ivermectin in an area endemic for Loa loa infection. The Lancet 350, 18\u201322 (1997).","journal-title":"The Lancet"},{"key":"322_CR34","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1017\/S0031182013001108","volume":"141","author":"MJ Taylor","year":"2014","unstructured":"Taylor, M. J., Hoerauf, A., Townson, S., Slatko, B. E. & Ward, S. A. Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis. Parasitology 141, 119\u2013127 (2014).","journal-title":"Parasitology"},{"key":"322_CR35","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/00001432-200112000-00011","volume":"14","author":"MJ Taylor","year":"2001","unstructured":"Taylor, M. J. & Hoerauf, A. A new approach to the treatment of filariasis. Current opinion in infectious diseases 14, 727\u2013731 (2001).","journal-title":"Current opinion in infectious diseases"},{"key":"322_CR36","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/S0140-6736(05)66591-9","volume":"365","author":"MJ Taylor","year":"2005","unstructured":"Taylor, M. J. et al. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. The Lancet 365, 2116\u20132121 (2005).","journal-title":"The Lancet"},{"key":"322_CR37","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.1371\/journal.ppat.0020092","volume":"2","author":"AY Debrah","year":"2006","unstructured":"Debrah, A. Y. et al. Doxycycline reduces plasma VEGF-C\/sVEGFR-3 and improves pathology in lymphatic filariasis. PLoS Pathog 2, e92 (2006).","journal-title":"PLoS Pathog"},{"key":"322_CR38","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1111\/j.1365-3156.2007.01949.x","volume":"12","author":"AY Debrah","year":"2007","unstructured":"Debrah, A. Y. et al. Macrofilaricidal effect of 4 weeks of treatment with doxycycline on Wuchereria bancrofti. Tropical Medicine & International Health 12, 1433\u20131441 (2007).","journal-title":"Tropical Medicine & International Health"},{"key":"322_CR39","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1086\/586753","volume":"46","author":"T Supali","year":"2008","unstructured":"Supali, T. et al. Doxycycline treatment of Brugia malayi-infected persons reduces microfilaremia and adverse reactions after diethylcarbamazine and albendazole treatment. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 46, 1385\u20131393, https:\/\/doi.org\/10.1086\/586753 (2008).","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"322_CR40","doi-asserted-by":"publisher","first-page":"702","DOI":"10.4269\/ajtmh.2009.09-0155","volume":"81","author":"S Mand","year":"2009","unstructured":"Mand, S. et al. Macrofilaricidal activity and amelioration of lymphatic pathology in bancroftian filariasis after 3 weeks of doxycycline followed by single-dose diethylcarbamazine. The American journal of tropical medicine and hygiene 81, 702\u2013711 (2009).","journal-title":"The American journal of tropical medicine and hygiene"},{"key":"322_CR41","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.actatropica.2012.10.011","volume":"125","author":"P Gayen","year":"2013","unstructured":"Gayen, P. et al. A double-blind controlled field trial of doxycycline and albendazole in combination for the treatment of bancroftian filariasis in India. Acta tropica 125, 150\u2013156 (2013).","journal-title":"Acta tropica"},{"key":"322_CR42","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00430-007-0062-1","volume":"197","author":"A Hoerauf","year":"2008","unstructured":"Hoerauf, A. et al. Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study. Medical microbiology and immunology 197, 295\u2013311, https:\/\/doi.org\/10.1007\/s00430-007-0062-1 (2008).","journal-title":"Medical microbiology and immunology"},{"key":"322_CR43","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s00436-008-1217-8","volume":"104","author":"A Hoerauf","year":"2009","unstructured":"Hoerauf, A. et al. Efficacy of 5-week doxycycline treatment on adult Onchocerca volvulus. Parasitology research 104, 437\u2013447, https:\/\/doi.org\/10.1007\/s00436-008-1217-8 (2009).","journal-title":"Parasitology research"},{"key":"322_CR44","doi-asserted-by":"publisher","first-page":"e660","DOI":"10.1371\/journal.pntd.0000660","volume":"4","author":"JD Turner","year":"2010","unstructured":"Turner, J. D. et al. Macrofilaricidal activity after doxycycline only treatment of Onchocerca volvulus in an area of Loa loa co-endemicity: a randomized controlled trial. PLoS Negl Trop Dis 4, e660, https:\/\/doi.org\/10.1371\/journal.pntd.0000660 (2010).","journal-title":"PLoS Negl Trop Dis"},{"key":"322_CR45","doi-asserted-by":"crossref","unstructured":"Debrah, A. Y. et al. Doxycycline leads to sterility and enhanced killing of female Onchocerca volvulus worms in an area with persistent microfilaridermia after repeated ivermectin treatment\u2013a randomized placebo controlled double-blind trial. Clinical Infectious Diseases civ363 (2015).","DOI":"10.1093\/cid\/civ363"},{"key":"322_CR46","first-page":"533","volume":"3","author":"A Hoerauf","year":"2002","unstructured":"Hoerauf, A., Adjei, O. & Buttner, D. W. Antibiotics for the treatment of onchocerciasis and other filarial infections. Current opinion in investigational drugs 3, 533\u2013537 (2002).","journal-title":"Current opinion in investigational drugs"},{"key":"322_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1756-3305-5-12","volume":"5","author":"A Albers","year":"2012","unstructured":"Albers, A. et al. Retarded Onchocerca volvulus L1 to L3 larval development in the Simulium damnosum vector after anti-wolbachial treatment of the human host. Parasites & vectors 5, 1 (2012).","journal-title":"Parasites & vectors"},{"key":"322_CR48","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1046\/j.1365-3156.2003.01040.x","volume":"8","author":"L Volkmann","year":"2003","unstructured":"Volkmann, L., Fischer, K., Taylor, M. & Hoerauf, A. Antibiotic therapy in murine filariasis (Litomosoides sigmodontis): comparative effects of doxycycline and rifampicin on Wolbachia and filarial viability. Tropical medicine & international health: TM & IH 8, 392\u2013401 (2003).","journal-title":"Tropical medicine & international health: TM & IH"},{"key":"322_CR49","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s00430-002-0174-6","volume":"192","author":"A Hoerauf","year":"2003","unstructured":"Hoerauf, A. et al. Doxycycline as a novel strategy against bancroftian filariasis-depletion of Wolbachia endosymbionts from Wuchereria bancrofti and stop of microfilaria production. Medical microbiology and immunology 192, 211\u2013216, https:\/\/doi.org\/10.1007\/s00430-002-0174-6 (2003).","journal-title":"Medical microbiology and immunology"},{"key":"322_CR50","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1093\/cid\/ciu1152","volume":"60","author":"M Walker","year":"2015","unstructured":"Walker, M. et al. Therapeutic efficacy and macrofilaricidal activity of doxycycline for the treatment of river blindness. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 60, 1199\u20131207, https:\/\/doi.org\/10.1093\/cid\/ciu1152 (2015).","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"322_CR51","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1016\/S0140-6736(05)66591-9","volume":"365","author":"MJ Taylor","year":"2005","unstructured":"Taylor, M. J. et al. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet 365, 2116\u20132121, https:\/\/doi.org\/10.1016\/S0140-6736(05)66591-9 (2005).","journal-title":"Lancet"},{"key":"322_CR52","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1016\/S0140-6736(00)04581-5","volume":"357","author":"A Hoerauf","year":"2001","unstructured":"Hoerauf, A., Mand, S., Adjei, O., Fleischer, B. & Buttner, D. W. Depletion of wolbachia endobacteria in Onchocerca volvulus by doxycycline and microfilaridermia after ivermectin treatment. Lancet 357, 1415\u20131416, https:\/\/doi.org\/10.1016\/S0140-6736(00)04581-5 (2001).","journal-title":"Lancet"},{"key":"322_CR53","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1086\/501351","volume":"42","author":"JD Turner","year":"2006","unstructured":"Turner, J. D. et al. A randomized, double-blind clinical trial of a 3-week course of doxycycline plus albendazole and ivermectin for the treatment of Wuchereria bancrofti infection. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 42, 1081\u20131089, https:\/\/doi.org\/10.1086\/501351 (2006).","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"322_CR54","doi-asserted-by":"publisher","first-page":"201617","DOI":"10.1155\/2011\/201617","volume":"2011","author":"AY Debrah","year":"2011","unstructured":"Debrah, A. Y. et al. Macrofilaricidal Activity in Wuchereria bancrofti after 2 Weeks Treatment with a Combination of Rifampicin plus Doxycycline. Journal of parasitology research 2011, 201617, https:\/\/doi.org\/10.1155\/2011\/201617 (2011).","journal-title":"Journal of parasitology research"},{"key":"322_CR55","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S0029-7844(97)00005-7","volume":"89","author":"AE Czeizel","year":"1997","unstructured":"Czeizel, A. E. & Rockenbauer, M. Teratogenic study of doxycycline. Obstetrics and gynecology 89, 524\u2013528, https:\/\/doi.org\/10.1016\/S0029-7844(97)00005-7 (1997).","journal-title":"Obstetrics and gynecology"},{"key":"322_CR56","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1186\/s13071-014-0472-z","volume":"7","author":"A Halliday","year":"2014","unstructured":"Halliday, A. et al. A murine macrofilaricide pre-clinical screening model for onchocerciasis and lymphatic filariasis. Parasit Vectors 7, 472, https:\/\/doi.org\/10.1186\/s13071-014-0472-z (2014).","journal-title":"Parasit Vectors"},{"key":"322_CR57","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1177\/1087057114551518","volume":"20","author":"RH Clare","year":"2015","unstructured":"Clare, R. H. et al. Development and validation of a high-throughput anti-Wolbachia whole-cell screen: a route to macrofilaricidal drugs against onchocerciasis and lymphatic filariasis. Journal of biomolecular screening 20, 64\u201369, https:\/\/doi.org\/10.1177\/1087057114551518 (2015).","journal-title":"Journal of biomolecular screening"},{"key":"322_CR58","doi-asserted-by":"crossref","unstructured":"Sharma, R. et al. Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis. Scientific reports 6 (2016).","DOI":"10.1038\/srep23458"},{"key":"322_CR59","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1086\/462426","volume":"192","author":"J Gilbert","year":"2005","unstructured":"Gilbert, J. et al. Antibiotic chemotherapy of onchocerciasis: in a bovine model, killing of adult parasites requires a sustained depletion of endosymbiotic bacteria (Wolbachia species). Journal of Infectious Diseases 192, 1483\u20131493 (2005).","journal-title":"Journal of Infectious Diseases"},{"key":"322_CR60","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1128\/AAC.50.3.922-927.2006","volume":"50","author":"BL Makepeace","year":"2006","unstructured":"Makepeace, B. L., Rodgers, L. & Trees, A. J. Rate of elimination of Wolbachia pipientis by doxycycline in vitro increases following drug withdrawal. Antimicrobial agents and chemotherapy 50, 922\u2013927 (2006).","journal-title":"Antimicrobial agents and chemotherapy"},{"key":"322_CR61","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1164\/rccm.201407-1264OC","volume":"191","author":"MJ Boeree","year":"2015","unstructured":"Boeree, M. J. et al. A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis. American journal of respiratory and critical care medicine 191, 1058\u20131065, https:\/\/doi.org\/10.1164\/rccm.201407-1264OC (2015).","journal-title":"American journal of respiratory and critical care medicine"},{"key":"322_CR62","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1087057113511270","volume":"19","author":"KL Johnston","year":"2014","unstructured":"Johnston, K. L., Ford, L. & Taylor, M. J. Overcoming the challenges of drug discovery for neglected tropical diseases: the A.WOL experience. Journal of biomolecular screening 19, 335\u2013343, https:\/\/doi.org\/10.1177\/1087057113511270 (2014).","journal-title":"Journal of biomolecular screening"},{"key":"322_CR63","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ijpddr.2014.09.001","volume":"4","author":"KL Johnston","year":"2014","unstructured":"Johnston, K. L. et al. Repurposing of approved drugs from the human pharmacopoeia to target Wolbachia endosymbionts of onchocerciasis and lymphatic filariasis. International journal for parasitology. Drugs and drug resistance 4, 278\u2013286, https:\/\/doi.org\/10.1016\/j.ijpddr.2014.09.001 (2014).","journal-title":"International journal for parasitology. Drugs and drug resistance"},{"key":"322_CR64","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0065-308X(05)61009-3","volume":"61","author":"BA Boatin","year":"2006","unstructured":"Boatin, B. A. & Richards, F. O. Control of onchocerciasis. Advances in parasitology 61, 349\u2013394 (2006).","journal-title":"Advances in parasitology"},{"key":"322_CR65","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.trstmh.2003.10.018","volume":"98","author":"J Kamgno","year":"2004","unstructured":"Kamgno, J., Gardon, J., Gardon-Wendel, N., Duke, B. O. & Boussinesq, M. Adverse systemic reactions to treatment of onchocerciasis with ivermectin at normal and high doses given annually or three-monthly. Transactions of the Royal Society of Tropical Medicine and Hygiene 98, 496\u2013504 (2004).","journal-title":"Transactions of the Royal Society of Tropical Medicine and Hygiene"},{"key":"322_CR66","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1111\/j.1469-0691.2011.03586.x","volume":"17","author":"A Hoerauf","year":"2011","unstructured":"Hoerauf, A., Pfarr, K., Mand, S., Debrah, A. & Specht, S. Filariasis in Africa\u2014treatment challenges and prospects. Clinical Microbiology and Infection 17, 977\u2013985 (2011).","journal-title":"Clinical Microbiology and Infection"},{"key":"322_CR67","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1475-2883-2-9","volume":"2","author":"HF McGarry","year":"2003","unstructured":"McGarry, H. F. et al. Evidence against Wolbachia symbiosis in Loa loa. Filaria journal 2, 9, https:\/\/doi.org\/10.1186\/1475-2883-2-9 (2003).","journal-title":"Filaria journal"},{"key":"322_CR68","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1186\/s13071-015-1283-6","volume":"8","author":"S Wanji","year":"2015","unstructured":"Wanji, S. et al. Relationship between oral declaration on adherence to ivermectin treatment and parasitological indicators of onchocerciasis in an area of persistent transmission despite a decade of mass drug administration in Cameroon. Parasit Vectors 8, 667, https:\/\/doi.org\/10.1186\/s13071-015-1283-6 (2015).","journal-title":"Parasit Vectors"},{"key":"322_CR69","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1007\/s00436-008-1133-y","volume":"103","author":"S Specht","year":"2008","unstructured":"Specht, S. et al. Efficacy of 2- and 4-week rifampicin treatment on the Wolbachia of Onchocerca volvulus. Parasitology research 103, 1303\u20131309, https:\/\/doi.org\/10.1007\/s00436-008-1133-y (2008).","journal-title":"Parasitology research"},{"key":"322_CR70","doi-asserted-by":"crossref","first-page":"878","DOI":"10.4269\/ajtmh.2007.77.878","volume":"77","author":"FO Richards Jr.","year":"2007","unstructured":"Richards, F. O. Jr. et al. No depletion of Wolbachia from Onchocerca volvulus after a short course of rifampin and\/or azithromycin. Am J Trop Med Hyg 77, 878\u2013882 (2007).","journal-title":"Am J Trop Med Hyg"},{"key":"322_CR71","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1093\/cid\/cir184","volume":"52","author":"J van Ingen","year":"2011","unstructured":"van Ingen, J. et al. Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment? Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 52, e194\u2013199, https:\/\/doi.org\/10.1093\/cid\/cir184 (2011).","journal-title":"Clinical infectious diseases: an official publication of the Infectious Diseases Society of America"},{"key":"322_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(16)30274-2","author":"MJ Boeree","year":"2016","unstructured":"Boeree, M. J. et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. The Lancet Infectious Diseases. https:\/\/doi.org\/10.1016\/S1473-3099(16)30274-2 (2016).","journal-title":"The Lancet Infectious Diseases"},{"key":"322_CR73","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1136\/thx.35.10.788","volume":"35","author":"G Acocella","year":"1980","unstructured":"Acocella, G., Brumfitt, W. & Hamilton-Miller, J. M. Evidence that rifampicin can be used safely for non-tuberculous diseases. Thorax 35, 788\u2013791 (1980).","journal-title":"Thorax"},{"key":"322_CR74","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1159\/000238355","volume":"31","author":"RN Gruneberg","year":"1985","unstructured":"Gruneberg, R. N., Emmerson, A. M. & Cremer, A. W. Rifampicin for non-tuberculous infections? Chemotherapy 31, 324\u2013328 (1985).","journal-title":"Chemotherapy"},{"key":"322_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1185\/03007995.2012.747952","volume":"29","author":"AM Baciewicz","year":"2013","unstructured":"Baciewicz, A. M., Chrisman, C. R., Finch, C. K. & Self, T. H. Update on rifampin, rifabutin, and rifapentine drug interactions. Current medical research and opinion 29, 1\u201312, https:\/\/doi.org\/10.1185\/03007995.2012.747952 (2013).","journal-title":"Current medical research and opinion"},{"key":"322_CR76","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1475-2883-4-4","volume":"4","author":"HF McGarry","year":"2005","unstructured":"McGarry, H. F., Plant, L. D. & Taylor, M. J. Diethylcarbamazine activity against Brugia malayi microfilariae is dependent on inducible nitric-oxide synthase and the cyclooxygenase pathway. Filaria journal 4, 4, https:\/\/doi.org\/10.1186\/1475-2883-4-4 (2005).","journal-title":"Filaria journal"},{"key":"322_CR77","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.molbiopara.2004.01.006","volume":"135","author":"HF McGarry","year":"2004","unstructured":"McGarry, H. F., Egerton, G. L. & Taylor, M. J. Population dynamics of Wolbachia bacterial endosymbionts in Brugia malayi. Molecular and biochemical parasitology 135, 57\u201367 (2004).","journal-title":"Molecular and biochemical parasitology"},{"key":"322_CR78","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1097\/FTD.0b013e31825c4ba6","volume":"34","author":"MN Neely","year":"2012","unstructured":"Neely, M. N., van Guilder, M. G., Yamada, W. M., Schumitzky, A. & Jelliffe, R. W. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R. Therapeutic drug monitoring 34, 467\u2013476, https:\/\/doi.org\/10.1097\/FTD.0b013e31825c4ba6 (2012).","journal-title":"Therapeutic drug monitoring"}],"updated-by":[{"DOI":"10.1038\/s41598-018-19723-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T00:00:00Z","timestamp":1516233600000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-00322-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-00322-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-00322-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T22:13:39Z","timestamp":1671747219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-00322-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,16]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["322"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-00322-5","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727416748.793533584","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,16]]},"assertion":[{"value":"4 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2018","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A correction to this article has been published and is linked from the HTML version of this paper. The error has been fixed in the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"210"}}